Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
In comparison to other psychedelics such as Psilocin, LSA and Ayahuasca, AL-LAD is significantly more stimulating and fast paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of 2C-B or 2C-I than Psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, organic in feel, multicoloured in scheme, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, round in its corners, unimmersive in depth and consistent in intensity. At higher dosages, it consistently results in states of Level 8A visual geometry over Level 8B.
AL-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.
The auditory effects of AL-LAD are common in their occurrence and exhibit a full range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
AL-LAD is non-habit forming and the desire to use it can actually decrease with use. It is considered self-regulating in the same manner as LSD and other classic psychedelics.
No physical dependence or withdrawal symptoms have been documented. As with LSD, AL-LAD does not appear to produce physical dependence, though formal studies have not been conducted.
The LD50 of AL-LAD is unknown. The exact toxic dose has not been determined as AL-LAD is a research chemical with very limited history of human usage and no formal toxicological studies have been conducted.
AL-LAD may act as a potential trigger for psychotic episodes in those with underlying psychiatric conditions. Those with a personal or family history of mental illness are advised not to use this substance. Delusions and adverse psychological reactions become more likely at higher doses, though overt psychosis appears uncommon in otherwise healthy individuals using the substance alone.
Seizures are rare but have been reported, primarily in those who are genetically predisposed to them, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment. Those with preexisting seizure disorders should avoid AL-LAD.
AL-LAD was first synthesized and described in the scientific literature in 1976. The compound received further attention in 1984 when researchers Andrew J. Hoffman and David Nichols investigated it as part of a broader series of LSD analogues, which also included ETH-LAD and PRO-LAD. This academic…
Not scheduled under the United Nations Convention on Psychotropic Substances
Not specifically scheduled, but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as a structural analogue of LSD.
Listed in a government decree banning psychoactive substances from the consumer market.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import for market distribution, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalty.
Although not officially scheduled by name, controlled as an LSD structural analogue under an amendment enacted June 1, 2015.
Specifically named as a controlled substance under Verzeichnis E, effective December 1, 2015, as part of a broader scheduling of 21 novel psychoactive substances.
Specifically named in the Misuse of Drugs Act 1971 as a Class A controlled substance. The UK Advisory Council on the Misuse of Drugs recommended scheduling on June 10, 2014, notably without identifying any harm associated with its use. The ban was enacted January 6, 2015 via The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
Specifically named on the list of controlled substances as of August 25, 2015.
Prohibited under national drug control legislation.
Designated as a controlled substance effective February 28, 2020.
Added to the Narcotic Drugs Punishments Act under Schedule I (substances without accepted medical use) on January 26, 2016. Listed in Medical Products Agency regulation HSLF-FS 2015:35 under multiple names including 6-allyl-6-nor-LSD.
Prohibited under national drug control legislation as of February 2016.
Not specifically scheduled at the federal level. However, as a structural analogue of the Schedule I substance LSD, it may be prosecuted under the Federal Analogue Act when sold, possessed, or consumed for human consumption. Research and analytical use are not subject to prosecution under this framework.
16 sources cited
